| Estela Del Carmen Ayala Meyer, MD | |
|
701 E. El Camino Real, Mountain View, CA 94040-2833 | |
| (650) 934-7144 | |
| Not Available |
| Full Name | Estela Del Carmen Ayala Meyer |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 20 Years |
| Location | 701 E. El Camino Real, Mountain View, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063608719 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A92908 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| El Camino Hospital | Mountain view, CA | Hospital |
| Good Samaritan Hospital | San jose, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physician Services At El Camino Hospital | 5698825016 | 33 |
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
An international task force, including two University of Massachusetts Amherst computer scientists, concludes in new research that mobile health (mHealth) technologies are a viable option to monitor COVID-19 patients at home and predict which ones will need medical intervention.
A recent group of researchers aimed to explore the impact of COVID-19 on the working practices of care home staff, particularly those caring for people with dementia.
Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
Dr. Ilse Levin specializes in internal medicine, but you could say she really focuses on incarceration medicine. Levin works at a community health center in southeast Washington, D.C., that pays a lot of attention to treating a population that is often left out of health care: newly released prisoners.
› Verified 9 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
An international task force, including two University of Massachusetts Amherst computer scientists, concludes in new research that mobile health (mHealth) technologies are a viable option to monitor COVID-19 patients at home and predict which ones will need medical intervention.
A recent group of researchers aimed to explore the impact of COVID-19 on the working practices of care home staff, particularly those caring for people with dementia.
Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
Dr. Ilse Levin specializes in internal medicine, but you could say she really focuses on incarceration medicine. Levin works at a community health center in southeast Washington, D.C., that pays a lot of attention to treating a population that is often left out of health care: newly released prisoners.
› Verified 9 days ago
| Entity Name | Physician Services At El Camino Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669575585 PECOS PAC ID: 5698825016 Enrollment ID: O20090605000358 |
News Archive
An international task force, including two University of Massachusetts Amherst computer scientists, concludes in new research that mobile health (mHealth) technologies are a viable option to monitor COVID-19 patients at home and predict which ones will need medical intervention.
A recent group of researchers aimed to explore the impact of COVID-19 on the working practices of care home staff, particularly those caring for people with dementia.
Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
Dr. Ilse Levin specializes in internal medicine, but you could say she really focuses on incarceration medicine. Levin works at a community health center in southeast Washington, D.C., that pays a lot of attention to treating a population that is often left out of health care: newly released prisoners.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Estela Del Carmen Ayala Meyer, MD 2350 W. El Camino Real, 2nd Floor, Mountain View, CA 94040-6203 Ph: () - | Estela Del Carmen Ayala Meyer, MD 701 E. El Camino Real, Mountain View, CA 94040-2833 Ph: (650) 934-7144 |
News Archive
An international task force, including two University of Massachusetts Amherst computer scientists, concludes in new research that mobile health (mHealth) technologies are a viable option to monitor COVID-19 patients at home and predict which ones will need medical intervention.
A recent group of researchers aimed to explore the impact of COVID-19 on the working practices of care home staff, particularly those caring for people with dementia.
Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
Dr. Ilse Levin specializes in internal medicine, but you could say she really focuses on incarceration medicine. Levin works at a community health center in southeast Washington, D.C., that pays a lot of attention to treating a population that is often left out of health care: newly released prisoners.
› Verified 9 days ago
Sevwandi De Silva, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7144 | |
Dr. Gayathri Thiru, M.D Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2490 Hospital Drive, Suite 212, Mountain View, CA 94040 Phone: 408-900-8077 Fax: 844-965-9436 | |
Dr. Shawn Mathew Jacob, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2500 Grant Rd, Mountain View, CA 94040 Phone: 650-940-7000 | |
Dr. Vibha Ramaswamy Iyengar, M.D, MPH Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7808 | |
Geoffrey Yoon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-404-8300 | |
Dr. David Alan Reinert, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7000 | |
Apurva Marfatia, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Medical Staff, Mountain View, CA 94040 Phone: 650-934-7144 |